[
  {
    "ts": null,
    "headline": "BlackRock Mid-Cap Growth Equity Fund Q1 2025 Commentary",
    "summary": "BlackRock Mid-Cap Growth Equity Fund posted returns of -13.35% (Institutional shares) and -13.43% (Investor A shares, without sales charge) for the first quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=419826848dc828c84815f383a1f91a4c6d02ff64335542e1a5911d29421eae27",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747351260,
      "headline": "BlackRock Mid-Cap Growth Equity Fund Q1 2025 Commentary",
      "id": 134489299,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2182036952/image_2182036952.jpg?io=getty-c-w1536",
      "related": "DXCM",
      "source": "SeekingAlpha",
      "summary": "BlackRock Mid-Cap Growth Equity Fund posted returns of -13.35% (Institutional shares) and -13.43% (Investor A shares, without sales charge) for the first quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=419826848dc828c84815f383a1f91a4c6d02ff64335542e1a5911d29421eae27"
    }
  },
  {
    "ts": null,
    "headline": "DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook",
    "summary": "Medical device company DexCom (NASDAQ:DXCM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be around $4.6 billion, close to analysts’ estimates. Its non-GAAP profit of $0.32 per share was in line with analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=7d17db524ea6d8e79556aa549e5e01d6e84cb5cde49139f2fb7ac25124b13d13",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747344069,
      "headline": "DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook",
      "id": 134499066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Medical device company DexCom (NASDAQ:DXCM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be around $4.6 billion, close to analysts’ estimates. Its non-GAAP profit of $0.32 per share was in line with analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=7d17db524ea6d8e79556aa549e5e01d6e84cb5cde49139f2fb7ac25124b13d13"
    }
  },
  {
    "ts": null,
    "headline": "5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil",
    "summary": "Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.",
    "url": "https://finnhub.io/api/news?id=65d3982951d4a9d3289d86500b5d69d83b7401bc8bebc04ccb579ba0ff45e8fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747310760,
      "headline": "5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil",
      "id": 134467965,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.",
      "url": "https://finnhub.io/api/news?id=65d3982951d4a9d3289d86500b5d69d83b7401bc8bebc04ccb579ba0ff45e8fc"
    }
  },
  {
    "ts": null,
    "headline": "Patient Monitoring Stocks Q1 Teardown: ResMed (NYSE:RMD) Vs The Rest",
    "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ResMed (NYSE:RMD) and the best and worst performers in the patient monitoring industry.",
    "url": "https://finnhub.io/api/news?id=8ca6bc9082b39fec03b95cdea27cb4998aaa694083e9fb549f9d90099bc8d4c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747280088,
      "headline": "Patient Monitoring Stocks Q1 Teardown: ResMed (NYSE:RMD) Vs The Rest",
      "id": 134465834,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ResMed (NYSE:RMD) and the best and worst performers in the patient monitoring industry.",
      "url": "https://finnhub.io/api/news?id=8ca6bc9082b39fec03b95cdea27cb4998aaa694083e9fb549f9d90099bc8d4c1"
    }
  }
]